Need help with MPN related out of pocket expenses?
The PAN Foundation is helping patients with Philadelphia chromosome negative myeloproliferative neoplasms (MPN) afford their out-of-pocket costs. If you’re a patient or caregiver looking for resources to help with your treatment-related costs, we encourage you to learn more about the PAN Foundation and its $3,250 annual assistance grants.
The PAN Foundation is a national organization that helps underinsured patients with life-threatening, chronic, and rare diseases get the medications and treatments they need by assisting with their out-of-pocket costs. You can find more information about their MPN fund below. If the fund is closed, sign up for the wait list to be notified when it’s time to apply.
The PAN Foundation’s Philadelphia chromosome negative myeloproliferative neoplasms (MPN) fund provides $3,250 per year in financial assistance to pay for the deductibles, copays, and coinsurance costs associated with MPN treatment. To qualify for funding, patients living with MPN must meet the following eligibility requirements:
Be getting treatment for Philadelphia chromosome negative myeloproliferative neoplasms.
Have an income that falls at or below 500% of the Federal Poverty Level.
Have health insurance that covers your qualifying medication or product.
Be prescribed a medication or product included in PAN’s list of covered medications.
Reside and receive treatment in the U.S. or U.S. territories (U.S. citizenship is not required).
Review the full eligibility criteria and check if you qualify.
How to apply
It’s easy to apply and you’ll learn if you’re approved for a grant immediately. If you’ve never applied at PAN before, call their contact center at 1-866-316-7263 Monday through Friday, 9 a.m. to 5:30 p.m. ET. If you have previously applied for a PAN grant or joined a disease fund wait list with PAN, you can apply through PAN’s online patient portal or by phone. Learn more about PAN’s application process.
Certain medicines listed may not be approved by the US Food and Drug Administration (FDA) for myelofibrosis but are recommended by the National Comprehensive Cancer Network (NCCN). MPN Research Foundation works with NCCN on the creation and updating of its MPN Patient Guidelines.
